Utah Medical Products Inc

Health Care
Medical/Dental Instruments
www.utahmed.com

Earnings Score
Moat Score
Safety Score

Market Cap $179.37M
PE 14
Debt $269.00K
Cash $83.33M
EV $96.32M
FCF $13.63M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$12.96M
EBIT	$15.86M
ROE	11%
ROA	13%
FCF	$13.63M
Equity	$117.05M
Growth Stability	78%
PE	13.84
PEG	2.28
PB	1.53
P/FCF	13.16
P/S	4.57
Price/Cash	0.46
Debt/Equity	0
Debt/FCF	0.02
Net Margins	31%
Gross Margins	58%
Op. Margins	40%
Earnings CAGR	4%
Sales Growth YoY	-14%
Sales Growth QoQ	6%
Sales CAGR	2%
FCF CAGR	5%
Equity CAGR	7%
Earnings Stability	0.23
Earnings Growth YoY	-23%
Earnings Growth QoQ	5%
Earnings CAGR 5Y	6%

Sales CAGR 5Y	0%
FCF CAGR 5Y	-4%
Equity CAGR 5Y	5%
Earnings CAGR 3Y	-9%
Sales CAGR 3Y	-9%
FCF CAGR 3Y	-12%
Equity CAGR 3Y	4%
Market Cap	$179.37M
Revenue	$39.27M
Dividend Yield	2%
Payout Ratio	32%
Assets	$122.52M
Total Debt	$269.00K
Cash	$83.33M
Shares Outstanding	3.28M
EV	96.32M
Earnings Score	9%
Moat Score	94%
Safety Score	96%
Final Score	66%
Working Capital	92.08M
Current Ratio	22.29
Gross Profit	$22.92M
Shares Growth 3y	-3%
Equity Growth QoQ	-0%
Equity Growth YoY	-8%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Utah Medical Products Inc is involved in the business of developing, manufacturing and distributing medical devices that are mainly proprietary, disposable and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals as well as outpatient clinics and physicians offices.

SEC Filings

Direct access to Utah Medical Products Inc (UTMD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Utah Medical Products Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Utah Medical Products Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 4%

Stability 23%

loading chart...

Utah Medical Products Inc Discounted Cash Flow

Fully customizable DCF calculator online for Utah Medical Products Inc.

Years

Calculation mode

= $191M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$14M	$14M	$15M	$16M	$17M	$17M	$18M	$19M	$20M	$21M	$22M	$221M
DCF		$13M	$12M	$12M	$11M	$11M	$10M	$9.8M	$9.4M	$8.9M	$8.5M	$85M
Value	$191M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	29%	31%	21%	44%	31%	26%	30%	32%	33%	34%	31%
ROA	-	21%	20%	19%	16%	12%	16%	17%	15%	14%	13%
ROE	-	18%	11%	21%	15%	11%	14%	14%	13%	12%	11%

Good Net Margins (31.32%)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	0	0	0	0	0	0	0.01	0.02	0.02
Debt over Equity	0	-	0	0	0	0	0	0	0	0	0
Growth Stability	-	-	-	100%	100%	78%	100%	100%	100%	87%	78%

Good Debt/FCF ratio (0.02)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (78%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-2%	5%	1%	12%	-10%	16%	7%	-4%	-19%	0%
Earnings YoY growth	-	2%	-30%	118%	-21%	-27%	37%	11%	1%	-17%	6%
Equity YoY growth	-	-1%	13%	14%	14%	2%	4%	7%	12%	-8%	5%
FCF YoY growth	-	-18%	36%	7%	1%	17%	7%	-2%	6%	-33%	-4%